ID | 1050 |
Name of the vaccine | Infanrix hexa |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | Babies and toddlers |
Description of the vaccine | Diphtheria, tetanus, pertussis (acellular, component), hepatitis B, poliomyelitis (inactivated) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed). |
Name of the manufacturer | GlaxoSmithKline Biologicals |
Name of the manufacturing country | Belgium |
Year of manufacture | 2000 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | Between 95 and 100%. |
Vaccine formulation | Powder and suspension |
Dosage | Two or three injections with at least 2 or 1 month gap. |
Mechanism of action | Make antibodies. |
Route of administration | Intramuscular |
Indications | 6-in-1 vaccine. |
Export | Marketing Authorisation Holder- GlaxoSmithKline UK Limited |
Approval | European Medicines Agency |
Adjuvant | NA |
Repurposing | For Diphtheria, haemophilus influenza type b, pertussis, hepatitis B, poliomyelitis. |
Side effects of vaccine | Sleepiness, loss of appetite, high temperature, swelling, pain, redness, unusual crying, feeling irritable. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01353703 |
Reference | https://www.medicines.org.uk/emc/files/pil.2586.pdf |
Other name | NA |
Additional Links | https://www.drugs.com/uk/infanrix-hexa.html
|